DEVONIAN HLTH GROUP INC - DVHGF STOCK NEWS

Devonian Health Group reported strong financial results for fiscal year 2024. Fourth quarter revenues surged 749% year-over-year to $9 Million, while annual revenues increased 660% to $17.8 Million. The company posted Q4 net income of $0.007 per share and an annual net loss of $0.008 per share. The growth was primarily driven by its subsidiary Altius Healthcare's DEXLANSOPRAZOLE launch, the only authorized generic in Canada for GERD treatment. Cash position improved to $9.9 million with reduced debt of $2.08 million. The company continues development of ThykamineTM for atopic dermatitis treatment.

Devonian Health Group Inc. (TSXv: GSD), a clinical stage botanical pharmaceutical , has announced the grant of stock options approved by its Board of Directors. The company, which focuses on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, has issued a total of 3,298,611 options to its officers.

The options come with an exercise price of $0.16 and are valid for a period of 10 years from the date of grant. Notably, these options are exercisable immediately upon grant, providing immediate potential value to the recipients. This move may be seen as a strategy to align the interests of the company's officers with those of the shareholders.

Devonian Health Group Inc. (TSXV: GSD; OTCQB: DVHGF) has announced two significant changes:

1. Amendment to Articles of Amalgamation: The company will create a new class of common shares, converting all existing subordinate voting shares into common shares. This reclassification, approved by shareholders on February 20, 2024, is expected to take effect on October 10, 2024. The new common shares will trade under the symbol "GSD" on the TSX Venture Exchange.

2. Management Change: Ms. Colette Laurin, Interim Chief Financial Officer, has resigned effective January 5, 2025. Devonian has initiated a search for her replacement.

These changes aim to simplify the company's share structure and manage a key leadership transition.

Devonian Health Group (TSXV: GSD; OTCQB: DVHGF) has announced its participation in Renmark Financial Communications Inc.'s Virtual Non-Deal Roadshow Series in Chicago on July 17, 2024. The event will feature a presentation by Luc Grégoire, President & CEO of Devonian, covering the company's latest investor presentation followed by a live Q&A session.

Stakeholders, investors, and interested individuals are invited to register for this live event. While registration may be , a replay will be available on the company's investor website after the event. Participants are advised to use the latest version of Google Chrome for optimal connectivity.

Devonian Health Group (OTCQB: DVHGF) will participate in Renmark Financial Communications' Virtual Non-Deal Roadshow Series on July 10, 2024, in Los Angeles. The event will feature a presentation by Luc Gregoire, President & CEO of Devonian, covering the latest investor updates, followed by a live Q&A session. Stakeholders and investors are invited to attend the live event via registration, though spaces are A replay will be available on the company’s investor website post-event. Attendees are advised to use the latest version of Google Chrome for optimal connectivity.

Devonian Health Group (TSXV: GSD; OTCQB: DVHGF) announced their participation in Renmark Financial Communications Inc.’s Virtual Non-Deal Roadshow Series in Boston on June 26, 2024. The event will feature the latest investor presentation from Mr. Luc Gregoire, President & CEO of Devonian. Stakeholders, investors, and individuals are invited to register and attend the live session. The presentation will conclude with a live Q&A. live event registration is available, but the replay will be accessible on the company's investor website.

To register, use the provided link and ensure you have the latest version of Google Chrome for optimal connectivity.

Devonian Health Group reported a breakout third quarter for 2024 with a 1,162% year-over-year revenue increase, driven by the launch of DEXLANSOPRAZOLE, a medication for GERD, by its subsidiary, Altius Health Care. For the quarter ending April 30, 2024, the company posted a net loss of $0.374 million, or $0.002 per share, an improvement from the $1.5 million loss, or $0.01 per share, in the same period last year. Year-to-date, distribution revenue rose 583% to $8.68 million, while net losses were reduced to $2.306 million from $3.736 million. Cash reserves stood at $3.5 million, offset by $2.16 million in debt. Key business initiatives included preparations for a phase II/III clinical study of Thykamine for pediatric eczema and the appointment of André Boulet as Chairman of the Board and COO. Additionally, Devonian engaged Renmark Financial Communications for investor relations services.

Devonian Health Group announced the appointment of Dr. André P. Boulet as Chairman of the Board and Chief Operating Officer. Dr. Boulet, the founder of Devonian, has been a Board member since 2015 and the Chief Scientific Officer since August 2022. He brings extensive experience in drug development, regulatory affairs, market access, financing, and restructuring. Dr. Boulet holds multiple degrees, including a Ph.D. in physiology-endocrinology and has completed postdoctoral and health economics training. This strategic leadership change aims to enhance the integration of Devonian's development strategy and manage key stakeholder relationships. Outgoing Chairman David Baker will remain a Board member.

Devonian Health Group Inc. (DVHGF) reported strong financial and business performance in the second quarter of 2024, with notable achievements in revenue growth, debt reduction, and patent advancements. The company's distribution revenue surged by 402% year over year, reaching $2.28 million for the quarter. Despite a net loss of $1.2 million, Devonian successfully extinguished its long-term debts and bolstered its leadership team. Additionally, the company obtained a U.S. patent for ThykamineTM to treat inflammatory bowel disease (IBD) and made progress in clinical studies for atopic dermatitis treatment. Devonian's strategic decisions, including a potential share consolidation, aim to enhance investor appeal and meet listing requirements on various stock exchanges.